Source comparison
Thymosin Alpha-1 Help Chronic Fatigue Research: Comparison Table
Thymosin Alpha-1 TLR9 agonist; restores T-cell proliferation; modulates Th1/Th2 balance Small RCTs, observational cohorts (n=30–90) 8–12 weeks for symptom improvement Elevated inflammatory markers, documented viral reactivation, illness duration <5 years Most
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 agonist; restores T-cell proliferation; modulates Th1/Th2 balance
- Small RCTs, observational cohorts (n=30–90)
- 8–12 weeks for symptom improvement
- Elevated inflammatory markers, documented viral reactivation, illness duration <5 years
- Most promising for post-viral fatigue with measurable immune dysfunction; limited utility in metabolic-driven fatigue
- Low-Dose Naltrexone
- Opioid receptor modulation; reduces neuroinflammation; increases endorphin production
- Multiple small trials (n=20–60); mixed results
- 4–8 weeks for initial response
- ME/CFS diagnosis, pain as prominent symptom, no contraindications to opioid antagonists
- Broader patient response than thymosin alpha-1 but lower magnitude of effect; symptom management rather than mechanism correction
- CoQ10 + NADH
- Mitochondrial electron transport support; ATP synthesis enhancement
- Cochrane review of 8 trials; moderate-quality evidence
- 6–12 weeks for energy improvement
- Oxidative stress markers, mitochondrial dysfunction on muscle biopsy (rare)
- Addresses metabolic component but ineffective if immune dysregulation is primary driver; works best as adjunct
- Rintatolimod (Ampligen)
- TLR3 agonist; interferon induction; antiviral activity
- Phase II/III trials (n=200+); FDA review ongoing
- 12–24 weeks for sustained benefit
- Severe ME/CFS (Karnofsky score <50), documented immune abnormalities
- Strongest evidence base but access limited; higher cost and injection frequency than thymosin alpha-1